Efficacy and safety of recombinant human interleukin-11 in the treatment of acute leukaemia patients with chemotherapy-induced thrombocytopenia: A systematic review and meta-analysis.

Abstract

Current meta-analysis was conducted aiming to assess the efficacy and safety of recombinant human interleukin-11 (rhIL-11) in the treatment of acute leukaemia (AL) patients with chemotherapy-induced thrombocytopenia (CIT). We searched PubMed, Embase, Chinese National Knowledge Infrastructure database (CNKI), Cochrane Library, and Wan Fang Database on 4 July 2018. Ten randomized controlled trials (RCTs) and two observational studies were included, which involved 754 AL patients with CIT. Pooled analysis demonstrated that rhIL-11 was beneficial on CIT: recovery time of platelet count to 50×109 /L [weight mean difference (WMD)=-4.19 days; 95% CI: -5.01, -3.37], recovery time of platelet count to 100×109 /L (WMD=-4.45days; 95% CI: -4.85, -4.06), platelet transfusion volume (WMD=-6.14U; 95% CI: -9.20, -3.09), and the rate of haemorrhage (RR=0.46; 95% CI: 0.36 to 0.61). Most adverse events associated with rhIL-11 were mild to moderate. Our findings suggest that rhIL-11 is effective and safe in the treatment of CIT in patients with AL.